Compare AbCellera Biologics Inc (ABCL) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Verisign, Inc. — how do they compare? AbCellera Biologics Inc trades at $10.16 (market cap $2.99B), while Verisign, Inc. trades at $283.38 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 8.7× AbCellera Biologics Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | VRSN | |
|---|---|---|
Market Cap | $2.99B | $26.00B |
Sector | Health | Technology |
52-Week High | $9.76 | $310.00 |
52-Week Low | $2.78 | $211.49 |
Enterprise Value | $2.58B | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
VeriSign (VRSN) trades at $283.56, down 3.33% today, amid mixed quarterly earnings but maintains a bullish technical trend with strong moving averages. The company reported Q2 2026 revenue of $435 million, up 6% year-over-year, with EPS of $2.38 beating estimates. Recent delegation of the .web domain and AI-driven registration growth support a positive outlook, though valuation ratios like P/E of 31.23 suggest a premium.
The stock offers upside to the consensus price target of $320, driven by domain growth and pricing power, but risks include high debt levels and reliance on .com/.net contracts. Analyst sentiment is bullish with 60% buy ratings, yet investors should monitor execution on guidance and contract renewals for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
